Equity multiplier, or assets relative to shareholders' equity, comes in at -0.92 for Neovasc Inc; that's greater than it is for merely 5.73% of US stocks.
As for revenue growth, note that NVCN's revenue has grown -78.93% over the past 12 months; that beats the revenue growth of merely 1.51% of US companies in our set.
Neovasc Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -75.63%, greater than the shareholder yield of only 5.29% of stocks in our set.
Stocks that are quantitatively similar to NVCN, based on their financial statements, market capitalization, and price volatility, are XLRN, SGMO, RMBS, MRUS, and STRO.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The Company also sells a line of biological tissue products that are used as components in third-party medical products including transcatheter heart valves. The company was founded in 2000 and is based in Richmond, Canada.
Following the earlier issuance to Strul of a convertible note in the principal amount of US$4 million and 2,573,959 warrants (the “Warrants”), the Company has raised aggregate gross proceeds of US$5 million (the “Offering”). Pursuant to the Offering the Company issued notes in the aggregate principal amount of US$5 million (the “2020 Notes”), convertible at $2.81525 per common share for 1,776,041 common shares, and 2,573,959 Warrants exercisable at $ 2.634 per Warrant share with a 4-year term.
Elective Interventional Procedures Resume in Germany Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 3, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Neovasc Reducer™ device ("Reducer") for the treatment of refractory angina was featured on the Hamburg-based German public television program NDR Visite. The ...
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Less invasive approach provides hope for the millions of patients that suffer from leaky mitral valves Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 27, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that the Company has filed for CE Mark for its Tiara TA Transapical ...
After a marked slowdown that began in March, Reducer implant rates in Germany, where the company has a direct sales team and NUB Status 1 designation for reimbursement, are once again approaching pre-COVID-19 levels. As previously discussed, the company is aware of the backlog of potential Reducer patients related to COVID-19 and the reduction in elective procedures in select European markets and we look forward to continued acceleration. The National Institute for Health and Care Excellence (NICE) Interventional Procedures Programme in the U.K. has invited Neovasc to participate in guidance development for Reducer treatment of refractory angina.